During the corresponding time, Aytu Biopharma Inc saw a revenue deteriorated by -0.91 % year on year, sequentially revenue grew by 38.86 %. While revenue at the Aytu Biopharma Inc's corporate clients
Aytu Biopharma Inc's Comment on Sales, Marketing and Customers
The company focuses on its core prescription business, primarily branded central nervous system (CNS) products. It holds an exclusive commercialization agreement for EXXUA, a first-in-class treatment for major depressive disorder (MDD) in the United States, launched in fiscal 2026. The business comprises EXXUA, an ADHD Portfolio, and a Pediatric Portfolio. Prescription products are mainly distributed in the United States through pharmaceutical wholesalers, distributors, pharmacies, and third-party logistics providers.
EXXUA is FDA-approved for MDD in adults and has been studied for generalized anxiety disorder (GAD) and hypoactive sexual desire disorder (HSDD). The ADHD Portfolio includes Adzenys and Cotempla, FDA-approved extended-release stimulant medications for attention deficit hyperactivity disorder (ADHD) in children and adolescents. The Pediatric Portfolio includes Karbinal ER, an extended-release antihistamine for allergic conditions in patients aged two years and older.
The company commercializes EXXUA through approximately 40 sales territories, while the ADHD and Pediatric Portfolios are currently non-promoted. The Aytu RxConnect patient support program operates through over 1,000 pharmacies, providing affordable copays and access for commercially insured patients, as well as support for healthcare professionals.
Customers and markets referenced in company filings include Acerus, Avrio Genetics, LLC, Customer A, Customer B, Customer C, Customer D, Innovus Pharmaceuticals, Inc., Medomie Pharma Ltd, and Neos Therapeutics.
Aytu Biopharma Inc’s Comment on Sales, Marketing and Customers
The company focuses on its core prescription business, primarily branded central nervous system (CNS) products. It holds an exclusive commercialization agreement for EXXUA, a first-in-class treatment for major depressive disorder (MDD) in the United States, launched in fiscal 2026. The business comprises EXXUA, an ADHD Portfolio, and a Pediatric Portfolio. Prescription products are mainly distributed in the United States through pharmaceutical wholesalers, distributors, pharmacies, and third-party logistics providers.
EXXUA is FDA-approved for MDD in adults and has been studied for generalized anxiety disorder (GAD) and hypoactive sexual desire disorder (HSDD). The ADHD Portfolio includes Adzenys and Cotempla, FDA-approved extended-release stimulant medications for attention deficit hyperactivity disorder (ADHD) in children and adolescents. The Pediatric Portfolio includes Karbinal ER, an extended-release antihistamine for allergic conditions in patients aged two years and older.
The company commercializes EXXUA through approximately 40 sales territories, while the ADHD and Pediatric Portfolios are currently non-promoted. The Aytu RxConnect patient support program operates through over 1,000 pharmacies, providing affordable copays and access for commercially insured patients, as well as support for healthcare professionals.
Customers and markets referenced in company filings include Acerus, Avrio Genetics, LLC, Customer A, Customer B, Customer C, Customer D, Innovus Pharmaceuticals, Inc., Medomie Pharma Ltd, and Neos Therapeutics.
Sources:
Aytu Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aytu Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aytu Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
357.44 %